Drugmaker Cipla saw a 6 per cent dip in profit after tax at ₹261 crore for the quarter ended March 31, against ₹276 crore in the corresponding period last year. Its net sales grew 27 per cent to ₹2,429 crore, (₹1917 crore). Domestic sales grew 19.3 per cent to ₹908 crore (₹761 crore). This was largely on the back of growth in the respiratory, anti-infective and cardiac therapies segments, Cipla said.

Export of active pharmaceutical ingredients grew 37 per cent to ₹239 crore during Q4 of FY13-14 (₹175 crore). And this was riding on growth in the anti-retroviral, anti-asthma and anti-allergic segments, the company added.

For the year ended March 31, 2014, Cipla clocked net sales of ₹9,752 crore and a net profit of ₹1,388 crore. The company had registered net sales of ₹8,086 crore last year, and a net profit of ₹1,544 crore. The yearly figures included relevant results of Cipla’s subsidiaries from the date they became arms of the company and, hence, the corresponding figures for the previous period are not comparable, Cipla clarified.

Related Topics